BioVaxys' COVID-19 vaccine shows positive early results

By The Science Advisory Board staff writers

November 11, 2020 -- BioVaxys Technology has announced its SARS-CoV-2 vaccine had a 96.4% positive antibody immune response, according to results from a preclinical animal study.

Charles River Laboratories, which contracted with BioVaxys, evaluated the antivirus immune response elicited by BVX-0320 by measuring the development of antibodies to the protein that binds the virus to human cells. Two injections of BVX-0320 along with the immunological adjuvant QS21 were given to 28 mice at four dosage levels. At week six, 96.4% developed positive antibody responses. Mice that received the QS21 adjuvant without BVX-0320 developed no antibody responses.

The companies are continuing to collect experimental data to determine the antibody levels induced by each dose of the vaccine and measure T-cell responses. Results are anticipated next month. Upon completion, BioVaxys plans to pursue regulatory approval for a phase I study of BVX-0320 in humans.


Copyright © 2020 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.